US & China Pharmaceutical Excipient DMF Registration & Joint Review Guide
Analyzing U.S. FDA Type IV DMF and China CDE registration pathways for excipients, guiding CTD Module 3 compilation for drug-excipient joint reviews.
Excipients do not receive standalone licenses; they undergo joint review with drug formulations. Under U.S. pathways, excipient firms file a Type IV DMF with the FDA, obtain a code, and issue Letters of Authorization (LOA). Under China pathways, firms register on the CDE portal, obtain a registration code showing as "I" (Inactive), which transitions to "A" (Active) upon drug approval.
CDE Regulatory Dossier Requirements for Purification Steps
China CDE reviews emphasize the synthetic chemistry and purification steps of excipients, requiring transparent reaction schemas and quality control thresholds.
- Process flowcharts: detailing raw material input ratios, temperature, solvent reuse, and crystallizing
- Structure proof: IR, NMR, or MS scans verifying molecular structures and polymorphism
- Impurity studies: developing specific HPLC methods to monitor potential degradation and catalysts
FAQ
What is a Letter of Authorization (LOA)?+
An LOA is a formal letter submitted by the excipient manufacturer to the agency, authorizing a drug customer to reference their DMF. This allows regulators to review the excipient’s proprietary data without exposing trade secrets to the drug maker.
Next steps
If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.
